Homologously recombinant slow growing mycobacteria and uses therefor

ABSTRACT

A method of transforming slow-growing mycobacteria, such as M. bovis BCG, M. leprae, M. tuberculosis M. avium, M. intracellulare and M. africanum; a method of manipulating genomic DNA of slow-growing mycobacteria through homologous recombination; a method of producing homologously recombinant (HR) slow-growing mycobacteria in which heterologous DNA is integrated into the genomic DNA at a homologous locus; homologously recombinant (HR) slow-growing mycobacteria having heterologous DNA integrated into their genomic DNA at a homologous locus; and mycobacterial DNA useful as a genetic marker.

RELATED APPLICATIONS

This application is a divisional of U.S. Ser. No. 08/095,734, filed Jul. 22, 1993, which is a Continuation-in-Part (CIP) of U.S. Ser. No. 07/711,334, filed Jun. 6, 1991, now abandoned, which is a CIP of U.S. Ser. No. 07/367,894, filed Jun. 19, 1989, now abandoned, and corresponding PCT/US90/03451, filed Jun. 18, 1990; and PCT/US89/02962, filed Jul. 7, 1989, which are/were combined and claimed priority to U.S. Ser. No. 07/361,944, filed Jun. 5, 1989, now U.S. Pat. No. 5,504,005, which is a CIP of U.S. Ser. No. 07/223,089, filed Jul. 22, 1988, now abandoned, and of U.S. Ser. No. 07/216,390, filed Jul. 7, 1988, now abandoned, which are CIPs of U.S. Ser. No. 07/163,546, filed Mar. 3, 1988, now abandoned, and corresponding PCT/US88/00614, filed Feb. 29, 1988; which is a CIP of U.S. Ser. No. 07/020,451, filed Mar. 2, 1987, now abandoned. The teachings of these related applications are incorporated herein by reference.

BACKGROUND OF THE INVENTION

The World Health Organization estimates that one in three human beings is believed to be infected with Mycobacterium tuberculosis (Styblo, K., Reviews of Infectious Diseases. Vol. II, Suppl. 2, March-April, 1989; Bloom and Murray, Science 257:1055-1067, 1992). Over the past decade, there has been a recent resurgence in the incidence of tuberculosis in developed countries that has coincided with the AIDS epidemic (Snider and Roper, N. England J. Med. 326:703-705 (1992)). Because of their impact as major human pathogens and as a result of their profound immunostimulatry properties, mycobacteria have long been intensively studied. In the early 1900s, an attenuated mycobacterium, Mycobacerium(M.) bovis Bacille Calmette-Guerin (M. bovis BCG or BCG), was isolated for use as a vaccine against tuberculosis (Calmette et al. Acad. Natl. Med. (Paris), 91:787-796, 1924; reviewed in Collins, F. M., Bacterial Vaccines (R. Germanier, ed.), Academic Press, pp. 373-418, 1984). Although the efficacy of this vaccine against tuberculosis varied considerably in different trials, and the reasons for its variable efficacy have yet to be resolved, BCG is among the most widely used human vaccines (Luelmo, F., Am. Rev. Respir. Dis. 125:70-72, 1982; Fine, P. E. M., Reviews of Infectious Diseases II (supp. 2), 5353-5359, 1989).

The recent application of molecular biological technology to the study of mycobacteria has led to the identification of many of the major antigens that are targets of the immune response to infection by mycobacteria (Kaufmann, S. H. E., Immunol. Today 11:129-136, 1990; Young, R. A., Ann. Rev. Immunol. 8:401-420, 1990; Young et al., Academic Press Ltd., London, pp. 1-35, 1990; Young et al., Mol. Microbiol. 6:133-145, 1992)) and to an improved understanding of the molecular mechanisms involved in resistance to antimycobacterial antibiotics (Zhang et al., Nature 358:591-593, 1992; Telenti et al., Lancet 341:647-650, 1993). The development of tools that permit molecular genetic manipulation of mycobacteria has also allowed the construction of recombinant BCG vaccine vehicles (Snapper et al., Proc. Natl. Acad. Sci. USA 85:6987-6991, 1988; Husson et al., J. Bacteriol. 172:519-524, 1990; Martin et al., B. Nature 345:739-743, 1990; Snapper et al., Mol. Microbiol. 4:1911-1919, 1990; Aldovini and Young, Nature 351:479-482, 1991; Jacobs et al., Methods Enzymol. 204:537-555, 1991; Lee et al., Proc. Natl. Acad. Sci. USA 88:3111-3115, 1991; Stover et al., Nature 351: 456-460, 1991; Winter et al., Gene 109:47-54, 1991; Donnelly-Wu et al., Mol. Microbiol. 7:407-417, 1993)). Genome mapping and sequencing projects are providing valuable information about the M. tuberculosis and M. leprae genomes that will facilitate further study of the biology of these pathogens (Eiglmeier et al., Mol. Microbiol., in press, 1993; Young and Cole, J. Bacteriol. 175:1-6, 1993).

Despite these advances, there are two serious limitations to our ability to manipulate these organisms genetically. First, very few mycobacterial genes that can be used as genetic markers have been isolated (Donnelly-Wu et al., Mol. Microbiol. 7:407-417, 1993)). In addition, investigators have failed to obtain homologous recombination in slow growing mycobacteria, such as M. tuberculosis and M. bovis BCG (Kalpana et al., Proc. Natl. Acad. Sci. USA 88:5433-5447, 1991; Young and Cole, J. Bacteriol. 175:1-6, 1993)), although homologous recombination has been accomplished in the fast growing Mycobacterium smegmatis (Husson et al., J. Bacteriol. 172: 519-524, 1990)).

SUMMARY OF THE INVENTION

Described herein is a method of transforming slow-growing mycobacteria, such as M. bovis BCG, M. leprae, M. tuberculosis M. avium, M. intracellulare and M. africanum; a method of manipulating genomic DNA of slow-growing mycobacteria through homologous recombination; a method of producing homologously recombinant (HR) slow-growing mycobacteria in which heterologous DNA is integrated into the genomic DNA at a homologous locus; homologously recombinant (HR) slow-growing mycobacteria having heterologous DNA integrated into their genomic DNA at a homologous locus; and mycobacterial DNA useful as a genetic marker.

Applicants have succeeded in introducing heterologous DNA into (i.e., transforming) slow-growing mycobacteria through the use of electroporation in water (rather than in buffer). In the present method of transforming slow-growing mycobacteria, heterologous DNA (such as linear DNA or plasmid DNA) and slow-growing mycobacteria (e.g., M. bovis BCG, M. leprae, M. tuberculosis M. avium, M. intracellulare and M. africanum) are combined and the resulting combination is subjected to electroporation at an appropriate potential and capacitance for sufficient time for the heterologous DNA to enter the slow growing mycobacteria, resulting in the production of transformed mycobacteria containing the heterologous DNA. In one embodiment, heterologous DNA and M. bovis BCG are combined and subjected to electroporation in water. In a particular embodiment, the M. bovis BCG-heterologous DNA combination is subjected to electroporation in water at settings of approximately 2.5 kV potential and approximately 25 μF capacitance. Optionally, prior to harvest, cells to be transformed are exposed to glycine (such as by adding 1-2% glycine to culture medium in which the slow-grow mycobacteria are growing) in order to enhance or improve transformation efficiencies. In one embodiment, 1.5% glycine is added to the culture medium 24 hours prior to harvesting of the cells, which are then combined with heterologous DNA to be introduced into the slow-growing mycobacteria. The resulting combination is subjected to electroporation, preferably in water, as described above.

In a further embodiment of the method of transforming slow growing mycobacteria, cultures of the cells are maintained in (continuously propagated in) mid-log growth, in order to increase the fraction of cells which are undergoing DNA synthesis (and which, thus, are competent to take up heterologous DNA). Cultures of cells maintained in log-phase growth are subjected to electroporation, preferably in water and, as a result, are transformed with the heterologous DNA. As described above, efficiency of transformation can be increased by exposing the slow-growing mycobacteria to glycine prior to electroporation. Thus, in this embodiment, slow-growing mycobacteria in log-phase growth are combined with heterologous DNA (e.g., plasmid DNA, linearized DNA) to be introduced into the slow-growing mycobacteria. The resulting combination is subjected to electroporation (preferably in water), under conditions (potential and capacitance settings and sufficient time) appropriate for transformation of the cells. Optionally, prior to electroporation, the log-phase cells are exposed to glycine (e.g., approximately 1-2% glycine added to culture medium) in order to enhance transformation efficiency.

Heterologous DNA introduced into slow-growing mycobacteria is DNA from any source other than the recipient mycobacterium. It can be homologous to DNA present in the recipient mycobacterial genomic DNA, nonhomologous or both. DNA which is homologous to mycobacterial genomic DNA is introduced into the genomic DNA by homologous recombination or integration. Alternatively, the heterologous DNA introduced by the present method can be nonhomologous and, thus, enter mycobacterial genomic DNA by random integration events or remain extrachromosomal (unintegrated) after it enters the mycobacterium. In addition, in one embodiment of the present method, nonhomologous DNA linked to or inserted within DNA homologous to genomic DNA of the recipient mycobacterium is introduced into genomic DNA of the recipient mycobacterium as a result of homologous recombination which occurs between genomic DNA and the homologous DNA to which the nonhomologous DNA is linked (or in which it is inserted). For example, as described herein, a mycobacterial gene which encodes a genetic marker has been identified and isolated and used to target homologous integration of heterologous DNA (DNA homologous to genomic DNA of the mycobacterial recipient, alone or in conjunction with DNA not homologous to genomic DNA of recipient mycobacteria) into genomic DNA of a slow-growing mycobacterium. Specifically, the M. bovis BCG gene encoding orotidine-5-monophosphate decarboxylase (OMP DCase) (uraA) has been isolated, as has DNA flanking OMP DCase. The OMP DCase gene and the flanking DNA have been sequenced. The mycobacterial DNA containing the uraA locus, modified to contain heterologous DNA (a selectable marker gene) has been used to carry out integration of the heterologous DNA (the mycobacterial DNA and the selectable marker gene) into mycobacterial genomic DNA, resulting in production of homologously recombinant mycobacteria containing the heterologous DNA of a homologous locus. Specifically, M. bovis BCG DNA containing the uraA locus and flanking sequences was modified to replace the OMP DCase coding sequence with the Kan^(r) selectable marker gene (aph). The resulting construct, which included approximately 1.5 kb uraA flanking sequences on each side of the selectable marker gene, was transformed into M. bovis BCG, using the method described above. M. bovis BCG cultures in mid-log growth were subjected to electroporation in water, resulting in transformation of cells with the construct. Transformants were selected for further study, which showed that all transformants assessed contained vector DNA integrated into the genome and that in some of the transformants, the transforming DNA had integrated at the homologous genomic locus. Thus, heterologous DNA of interest has been introduced into genomic DNA of slow-growing mycobacteria through homologous recombination, to produce homologously recombinant slow-growing mycobacteria in which the heterologous DNA is integrated into the homologous genomic locus (a genomic locus homologous to at least a portion of the heterologous DNA).

Heterologous DNA which includes DNA homologous to genomic DNA of the recipient mycobacterium (homologous DNA) and DNA which is not homologous to genomic DNA of the recipient mycobacterium (nonhomologous DNA) can be introduced into (transformed into) slow growing mycobacterium by the present method for several purposes. As described herein, heterologous nonhomologous DNA encoding a product to be expressed by the resulting homologously recombinant slow-growing mycobacterium has been introduced into mycobacterial genomic DNA at a locus homologous with additional sequences to which the nonhomologous DNA is linked. In this embodiment, the DNA construct transformed into recipient slow-growing mycobacteria comprises homologous DNA, which directs or targets introduction of the heterologous DNA into the homologous locus of the mycobacterial genome, and nonhomologous DNA, which is expressed in transformed homologously recombinant mycobacteria. In this embodiment, the nonhomologous DNA is introduced into mycobacterial genomic DNA in such a manner that it is added to the genomic DNA or replaces genomic DNA. In a second embodiment, heterologous DNA integrated into genomic DNA is not expressed in the recipient cells. In this embodiment, the DNA construct includes homologous DNA for targeting into a homologous genomic locus and DNA which acts to knock out (inactivate) or activate a resident mycobacterial gene. In the case of inactivation, the mycobacterial gene is "knocked out", in the sense that it is rendered inactive by addition of DNA whose presence interferes with its ability to function, by removal or replacement of sequences necessary for it to be functional or by its complete removal from the mycobacterial genome. In the case of activation, the heterologous DNA integrated into the genomic DNA turns on or enhances expression of a mycobacterial gene, such as by introducing a heterologous promoter which controls the mycobacterial gene expression. In the embodiment in which heterologous DNA affects expression of an endogenous mycobacterial gene, the homologous DNA can serve both functions (i.e., the targeting and inactivation/activating functions); if that is the case, the DNA construct includes only homologous DNA. Alternatively, the DNA construct can include homologous DNA (for targeting purposes) and nonhomologous DNA (for altering function of the mycobacterial gene).

Homologously recombinant slow-growing mycobacteria of the present invention are useful, for example, as vehicles in which proteins encoded by the heterologous nonhomologous DNA are expressed. They are useful as vaccines, which express a polypeptide or a protein of interest (or more than one polypeptide or protein), such as an antigen or antigens of one or more pathogens against which protection is desired (e.g., to prevent or treat a disease or condition caused by the pathogen). Pathogens of interest include viruses, retroviruses, bacteria, mycobacteria, other microorganisms, organisms or substances (e.g., toxins or toxoids) which cause a disease or condition to be prevented, treated or reversed. The homologously recombinant slow-growing bacteria can also be used to express enzymes, immunopotentiators, lymphokines, pharmacologic agents, antitumor agents (e.g., cytokines), or stress proteins (useful for evoking or enhancing an immune response or inducing tolerance in an autoimmune disease). For example, homologously recombinant slow-growing mycobacteria of the present invention can express polypeptides or proteins which are growth inhibitors or are cytocidal for tumor cells (e.g., interferon α, β or γ, interleukins 1-7, tumor necrosis factor (TNF) α or β) and, thus, are useful for treating certain human cancers (e.g., bladder cancers, melanomas). Homologously recombinant slow-growing mycobacteria of the present invention are also useful vehicles to elicit protective immunity in a host, such as a human or other vertebrate. They can be used to produce humoral antibody immunity, cellular immunity and/or mucosal or secretory immunity. The antigens expressed by the homologously recombinant slow-growing mycobacteria, useful as vaccines or as diagnostic reagents, are also the subject of the present invention. In addition, homologously recombinant slow-growing mycobacteria of the present invention are useful as vaccines in which the heterologous DNA introduced through homologous integration is not itself expressed, but acts to knock out a mycobacterial gene necessary for pathogenicity of the slow-growing mycobacterium or its growth in vivo. Such homologously recombinant slow-growing mycobacteria are useful as vaccines to provide protection against diseases caused by the corresponding wild-type mycobacterium or as a vaccine vehicle which contains a gene(s) encoding an antigen(s) of a different pathogen(s) (e.g., as a vaccine to provide protection against an organism other than the corresponding wild-type mycobacterium or against a toxin or toxoid).

The vaccine of the present invention has important advantages over presently available vaccines. For example, mycobacteria have adjuvant properties; they stimulate a recipient's immune system to respond to other antigens with great effectiveness. In addition, the mycobacterium stimulates long-term memory or immunity. This means that a single (one time) inoculation can be used to produce long-term sensitization to protein antigens. Long-lasting T cell memory, which stimulates secondary antibody response neutralizing to the infectious agent or toxic. This is particularly useful, for example, against tetanus and diphtheria toxins, pertussis, malaria, influenza, herpes viruses and snake venoms.

BCG in particular has important advantages as a vaccine vehicle. For example, it can be used repeatedly in an individual and has had a very low incidence of adverse effects. In addition, BCG, as well as other mycobacteria, have a large genome (approximately 3×10⁶ bp in length). As a result, a large amount of heterologous DNA can be accommodated within (incorporated into) the mycobacterial genome, which means that a large gene or multiple genes (e.g., DNA encoding antigens for more than one pathogen) can be inserted into genomic DNA, such as by homologous recombination.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a structural and functional map of the M. bovis BCG uraA locus, in which a restriction map of the uraA locus and the recombinant insert DNAs for several plasmids used to study this region are depicted. The relative positions of the BCG uraA gene and the portions of other genes identified are summarized graphically and the ability of each recombinant to complement the E. coli pyrF mutant is indicated.

FIGS. 2A-2D is the nucleic acid sequence of the BCG uraA locus (Seq ID No. 1) and the predicted protein products (Seq ID No. 2).

FIG. 3 is a schematic representation of integration by homologous recombination in BCG. The uraA locus in wild-type BCG (top), the transforming DNA (middle) and a BCG transformant in which the transforming DNA fragment has integrated via homologous recombination (bottom) are represented.

FIG. 4 is a schematic representation of the Southern analysis of the BCG transformant represented in FIG. 3.

FIG. 5 shows the results of Southern blot analysis of genomic DNA isolated from wild-type BCG (WT) and a BCG transformant (6015-9). The positions of DNA markers are indicated to the right and the apparent size of each of the hybridizing DNA bands is indicated to the left.

DETAILED DESCRIPTION OF THE INVENTION

As described herein, Applicants have demonstrated introduction of heterologous DNA into slow-growing mycobacteria (transformation of heterologous DNA into slow-growing mycobacteria) and incorporation of heterologous DNA at a homologous locus in genomic DNA of slow-growing mycobacterial (integration of heterologous DNA into the genomic DNA through homologous recombination). As a result, they have produced homologously recombinant slow-growing mycobacteria having heterologous DNA integrated at a homologous locus in their genomic DNA. In particular, as described herein, Applicants have introduced heterologous DNA into M. bovis BCG (BCG) and demonstrated that it is present in the resulting homologously recombinant BCG at a genomic location homologous with sequences present in the DNA construct transformed into the BCG. The DNA construct introduced into BCG by the method described herein included heterologous DNA containing the uraA locus (homologous DNA) and nonhomologous DNA (a selectable marker gene); the heterologous homologous DNA flanked the nonhomologous DNA in the construct. Both the heterologous homologous DNA and the heterologous nonhomologous DNA in the DNA construct were shown to have integrated into the genome of the recipient mycobacterial cells at a homologous locus (a genomic locus homologous with the DNA including and/or flanked by the homologous DNA in the DNA construct).

As a result of the work described herein, a method of transforming slow growing mycobacteria, a method of introducing heterologous DNA into genomic DNA of a slow growing mycobacterium through integration at a homologous locus, DNA constructs useful in the method of introducing heterologous DNA into a homologous locus in genomic DNA of a slow growing mycobacteria, homologously recombinant slow growing mycobacteria which contain heterologous DNA at a homologous locus in their genomic DNA, a BCG gene encoding orotidine-5'-monophosphate decarboxylase (BCG OMP DCase) and homologously recombinant slow growing mycobacteria useful as vaccines are available. The following is a description of the present method, DNA constructs and vaccines, as well as the isolated BCG OMP DCase gene and its use.

The present invention includes an improved method of transforming slow growing mycobacteria. In the present method, slow growing mycobacteria are subjected to electroporation in water, preferably after exposure to (culturing in the presence of) glycine prior to electroporation and preferably also while they are in mid-log growth. Slow growing mycobacteria to be transformed with heterologous DNA are combined with the heterologous DNA (which can be plasmid/circular DNA or linear DNA) in water. The resulting combination is subjected to electroporation under conditions (e.g., potential, capacitance and time) sufficient for entry of the heterologous DNA into the slow growing mycobacteria. Electroporation is carried out at approximately 2 to 2.5 kV potential and approximately 1 to 125 μF capacitance for approximately 4 to 40 milliseconds. In a specific embodiment, slow growing mycobacterial cells are electroporated in water at approximately 2.5 kV potential and approximately 25 μF capacitance for 5-6 milliseconds. In a further embodiment, slow growing mycobacteria to be transformed are exposed to glycine (e.g., 1 to 2% glycine) by addition of glycine to culture medium prior to harvest of the cells. In a particular embodiment, slow growing mycobacteria are exposed to 1.5% glycine, which is added to culture medium, for approximately 24 hours prior to harvest of the cells for transformation. In another embodiment, slow-growing mycobacteria are in mid-log growth when they are transformed. The cells can also have been exposed to glycine, as described above, prior to electroporation, although that is not necessary. The mid-log slow growing mycobacteria are combined with heterologous DNA to be introduced into them and subjected to elecroporation in water, as described above, resulting in transformation of the heterologous DNA into slow growing mycobacteria in the combination.

The heterologous DNA introduced into slow growing mycobacteria by the present method is DNA obtained from any source other than the mycobacterium into which it is being introduced. It can be of viral, bacterial, mycobacterial, invertebrate or vertebrate (including human and other mammalian) origin, can be obtained from other organisms, such as parasites, or can be produced to have the same nucleic acid sequence as the DNA in its naturally occurring source. Alternatively, it can be modified DNA. The DNA introduced can be plasmid (circular) DNA or linear DNA. The heterologous DNA contains DNA homologous to a locus in genomic DNA of the recipient slow growing mycobacteria, DNA nonhomologous to a locus in genomic DNA of the recipient cells or both. It is possible to combine slow growing mycobacteria and a DNA construct in which the heterologous DNA is only nonhomologous DNA and carry out the present method of transformation, if the goal is to transform slow growing mycobacteria with greater efficiency than is possible with existing methods. Heterologous DNA introduced in this manner will integrate randomly into genomic DNA.

In order to produce homologously recombinant slow growing mycobacteria through homologous integration between mycobacterial genomic DNA and heterologous DNA, the DNA construct must include sufficient DNA homologous with mycobacterial DNA to cause integration of the construct into a homologous genomic locus. If only homologous DNA is present in the DNA construct used (e.g., in a construct introduced in order to knock out or activate endogenous mycobacterial DNA), at least 400 bp of homologous DNA will generally be used. If the DNA construct includes homologous DNA (for directing or targeting introduction into mycobacterial genomic DNA) and nonhomologous DNA (e.g., DNA encoding a product to be expressed in homologously recombinant slow growing mycobacteria), there is homologous DNA on both sides of (flanking both ends of) the nonhomologous DNA. In general, there will be at least approximately 250 bp of homologous DNA on each side of the nonhomologous DNA, although shorter flanking homologous sequences can be used, provided that they are of sufficient length to undergo homologous recombination with genomic sequences, resulting in their introduction into mycobacterial genomic DNA (alone or in conjunction with nonhomologous DNA with which the homologous DNA is present in the DNA construct). In the embodiment described in the examples, 1.5 kb of homologous DNA (1.5 kb of uraA flanking sequence) has been shown to result in homologous integration, along with nonhomologous DNA, into the uraA locus of M. bovis BCG.

The homologous DNA present in the DNA construct can be any DNA homologous to DNA present in genomic DNA of the recipient slow growing mycobacterium. Specifically described herein is the isolation and sequencing of the M. bovis BCG OMP DCase gene (uraA) and its use to introduce heterologous nonhomologous DNA into M. bovis BCG genomic DNA at a homologous locus. As described in the examples, a BCG DNA fragment which included the OMP DCase coding sequence was modified to remove the OMP DCase coding sequence and replace it with heterologous nonhomologous DNA encoding a selectable marker gene (i.e., the Kan^(r) (aph) gene). Specifically, the DNA construct was made by removing the OMP DCase coding sequence from a 4.4 kb BCG DNA fragment containing uraA and replacing it with the Kan^(r) gene (aph), to produce a DNA fragment in which the selectable marker gene is flanked by 1.5 kb uraA DNA (to direct homologous recombination or integration of the homologous DNA and, along with it, the nonhomologous DNA into mycobacterial genomic DNA). All or a portion of the OMP DCase gene can be used, with similar modifications, as a component of a DNA construct including other heterologous nonhomologous DNA to be introduced into M. bovis BCG genomic DNA at the uraA locus. Alternatively, other M. bovis BCG genes can be used as the heterologous homologous component of a DNA construct useful for introducing heterologous nonhomologous DNA into the mycobacterium. Similarly, DNA from other slow growing mycobacteria (e.g., M. leprae, M. tuberculosis, M. avium, M. africanum) can be incorporated into a DNA construct to be used for homologous recombination in the respective slow growing mycobacteria.

The heterologous nonhomologous DNA in the DNA construct introduced into slow growing mycobacteria by the present method can be any DNA which is expressed in the slow-growing mycobacteria or which is not expressed in the recipient mycobacteria but alters mycobacterial protein expression or function. For example, the heterologous nonhomologous DNA can be DNA encoding an antigen(s) of a pathogen or pathogens. A pathogen is any virus, microorganism, other organism or substance (e.g., toxins, toxoids) which causes a disease or undesirable condition. Homologously recombinant slow growing mycobacteria which express a protein antigen(s) from malaria sporozoites, malaria merozoites, diphtheria toxoid, tetanus toxoid, Leishmania, Salmonella, M. africanum, M. intracellulare, M. avium, treponema, pertussis, herpes virus, measles virus, mumps, Shigella, Neisseria, Borrelia, rabies, poliovirus, human immunodeficiency virus (HIV), Simian immunodeficiency virus (SIV), snake venom, insect venom or vibrio cholera can be produced using the method of the present invention. Homologously recombinant M. bovis BCG, which, in a nonhomologously recombinant form, has long been successfully administered as a vaccine in humans can be used. The DNA encoding the protein antigen(s) can be obtained from sources in which it naturally occurs or can be produced through known recombinant techniques or known chemical synthetic methods. For example, the DNA can be produced by genetic engineering methods, such as cloning or by the polymerase chain reaction (PCR).

A multipurpose or multifunctional vaccine (one which contains and expresses heterologous DNA encoding antigens from more than one pathogen) can be produced by the present method. In this embodiment, one or more DNA constructs are used to introduce heterologous homologous DNA and heterologous nonhomologous DNA (DNA encoding an antigen against which protection is desired) into the slow growing mycobacterium. If one construct is used, it includes DNA encoding the antigens of interest, flanked by homologous DNA sufficient for introduction of the heterologous DNA into a homologous locus in the mycobacterium. More than one construct can be used; in this case, each includes homologous DNA and nonhomologous DNA encoding an antigen of interest. A multifunctional vaccine of the present invention can be homologously recombinant BCG which contains, within its genomic DNA, a gene encoding an antigen for M. leprae, a gene encoding an antigen for M. tuberculosis, a gene encoding an antigen for malaria and a gene encoding an antigen for Leishmania; these sequences are flanked by heterologous sequences homologous with BCG DNA and are introduced into the BCG genome by homologous integration.

It is not necessary that heterologous nonhomologous DNA be expressed by homologously recombinant slow growing mycobacteria of the present invention or even that there be heterologous nonhomologous DNA present. For example, in one embodiment, heterologous nonhomologous DNA is incorporated into genomic DNA of slow growing mycobacteria for the purpose of inactivating an endogenous mycobacterial gene, such as a gene necessary for the pathogenicity of the mycobacterium. Any gene involved in metabolism necessary for pathogenicity of the slow growing mycobacterium (or for its growth in humans or other animals) but whose absence (e.g., from being knocked out) does not prevent it from being cultured can be targeted for inactivation. For example, the AROA gene of M. tuberculosis can be inactivated. In another embodiment, heterologous nonhomologous DNA is introduced in order to activate or turn on an endogenous mycobacterial gene. In either case, the heterologous nonhomologous DNA need not be expressed.

Heterologous DNA can be homologous DNA only; it is not necessary that heterologous nonhomologous DNA be present. For example, homologous DNA can be introduced into an endogenous mycobacterial gene (such as one essential for the pathogenicity of a slow growing mycobacterium) in order to disrupt or inactivate that gene. This is particularly useful in those embodiments in which an attenuated or disabled mycobacterium is desired, such as for use as a vaccine to elicit an immune response against the mycobacterium itself or as a vehicle to be used in a similar manner to that in which homologously recombinant BCG can be used (to express antigens of other pathogens).

Homologously recombinant slow growing mycobacteria of the present invention can be administered by known methods and a variety of routes (e.g., intradermally, intramuscularly, intravenously). They are useful as vehicles in which the heterologous nonhomologous DNA is expressed and as modified slow grow mycobacteria (e.g., mycobacteria with reduced or abolished pathogenicity) which are disabled or attenuated and, thus, useful as vaccines.

The present invention will now be illustrated by the following examples, which are not to be considered limited in any way.

MATERIALS AND METHODS

Strains and plasmids. M. bovis BCG used for DNA isolation and subsequent construction of the recombinant BCG plasmid and λgt11 libraries was the Montreal Strain, ATCC #35735. M. bovis BCG was grown in Middlebrook 7H9 media, supplemented with 0.05% Tween 80, as described in Aldovini and Young, Nature 351:479-482, (1991). E. coli strain Y1107 (pyrF::Mu trpam lacZam hsdR- m+ su-) was obtained from D. Botstein. Plasmids were propagated in the E. coli strain DH5α from Bethesda Research Laboratories. E. coli cultures used for plasmid selection were grown in Luria Bertani broth or agar with 50 μg/ml ampicillin. Phage M13 used for the production of single stranded DNA were propagated in E. coli strain JM101 from New England BioLabs. JM101 was grown in YT medium (Maniatis). Genomic libraries were generated using pUC19 from Bethesda Research Laboratories. Plasmid pY6002 (Husson et al., J. Bacteriol., 172:519-524 1990) was the source of the 1.3 kb BamHI DNA fragment containing the amino-glycoside phosphotransferase gene aph.

Enzymes. Klenow fragment of E. coli DNA polymerase was supplied by Promega. T7 polymerase, and Taq polymerase (Sequenase and Taquence) were provided by United States Biochemical.

Recombinant DNA library construction. To isolate BCG DNA, cells were harvested by centrifugation, washed, and resuspended in 50 mM Tris (pH 8.0), 10 mM EDTA, 10% sucrose, and 0.5 mg/ml lysozyme, and incubated at 37 degrees for one hour. EDTA was then added to 1%, and the mixture was incubated at room temperature for 15 minutes. Three phenol/chloroform extractions were performed, followed by RNase treatment, phenol/chloroform extraction, chloroform extraction and ethanol precipitation. The DNA was then resuspended in TE buffer, (10 mM Tris pH 7.5, imM EDTA).

To construct the plasmid library, the DNA was subjected to partial digestion with Sau3A and DNA fragments of 2-6 kb were isolated by agarose gel electrophoresis onto DE81 paper and eluted in buffer containing 10 mM Tris, HCl, 1M NaCl and 1 mM EDTA. The DNA fragments were then phenol-chloroform extracted, ethanol precipitated and ligated into BamH1 digested, calf-intestinal phosphatase treated pUC19 plasmid vector. E. coli cells were transformed with the ligated mixture, and approximately 4×10⁵ recombinants were obtained. Plasmid DNA was obtained from the pool of transformed colonies using an alkaline lysis method.

The λgt11 library was constructed using a procedure described by Young. (Young, R. A., et al., Proc. Natl. Acad. Sci., USA, 82:2583-2587 (1985)). Briefly, BCG genomic DNA was subjected to random partial digestion with DNase I, EcoRI linkers were added to the digestion products, and DNA fragments of 4-8 kb were isolated by agarose gel electrophoresis and electroelution. The DNA fragments were then ethanol precipitated and ligated into EcoRIdigested λgt11 arms. The ligation mixture was packaged into λ heads and the packaging mixture was used to infect E. coli. Approximately 5×10⁶ recombinants were obtained.

EXAMPLE 1

Isolation of BCG OMP DCase gene by complementation and plasmid DNA manipulation. The BCG recombinant library was used to transform the E. coli strain Y1107. Twenty-one transformants capable of growing in the absence of uracil were isolated, of which six were chosen for further evaluation by restriction analysis. Plasmid DNA was isolated by alkaline lysis from cells grown in liquid culture, and restriction analysis indicated that all of these plasmids contained the same or very similar insert DNAs. One of these clones (pY6006) was used for further study (see FIG. 1). A 0.6 kb BamHI DNA fragment from pY6006 was used to screen the λgt11 library, leading to the isolation of phage Y3030. This phage carries a 5.6 kb EcoRI BCG DNA insert containing the OMP DCase gene. This insert DNA was subcloned into pGEMz(f+) to generate pY6011. The 4.4 kb SacI-EcoRI fragment of the Y3030 insert was subcloned into pUC19 to generate pY6014. Plasmid pY6015 was derived from pY6014 by replacing uraA sequences with the aph gene; a 1.15 kb HincII DNA fragment containing uraA sequences was removed by partial HincII digestion of pY6014 DNA, and it was replaced with a 1.3 kb BamHI fragment containing aph from pY6002 that was blunt-ended with Klenow.

DNA Sequence analysis. The M. bovis BCG uraA gene was sequenced from the 4.4 kb SacI-EcoRI fragment of the λgt11 phage Y3030 cloned into M13 in both orientations. The same DNA fragment was subcloned into pUC19 to generate pY6014 for further manipulation. Single strand DNA for sequence analysis was prepared from M13 grown in JM101 (Viera and Messing, Methods Enzymol., 153:3-11 1987). Both DNA strands were sequenced using the dideoxy-method of Sanger (Sanger et al., Proc. Natl. Acad. Sci. USA 74:5463-5467, 1977). Mycobacterial DNA has a high GC content, and two different strategies were used to reduce band compression and other artifacts due to high G+C content. A subset of the reactions was carried out using Taq polymerase at high temperature (70° C.). In addition, dGTP and dITP were used in independent sequence reactions (Kimsey and Kaiser, J. Biol. Chem. 267:819-824, 1992).

RESULTS

Isolation of the BCG OMP decarboxylase gene by genetic complementation. The complementation strategy employed to isolate the BCG OMP DCase gene was similar to that employed previously to isolate the homologous gene in M. smegmatis (Husson et al., J. Bacteriol. 172:519-524, 1990). A recombinant library was constructed in the E. coli vector pUC19 using size selected BCG genomic DNA fragments from a partial SauIIIA digest. An E. coli pyrF mutant strain (Y1107) was transformed with this library and cells were plated on medium lacking uracil to select for uracil prototrophs, and on rich medium containing ampicillin to ascertain the transformation frequency and to estimate the fraction of transformants that were able to complement the E. coli pyrF defect. Approximately 0.05% of the cells transformed with the recombinant library became uracil prototrophs. DNA clones were obtained from six colonies able to grow in the absence of uracil, and restriction analysis revealed that these clones contained the same insert DNA. One of these clones, pY6006, was subjected to further study (FIG. 1).

To identify, the portion of the 3.5 kb insert DNA pY6006 that was responsible for complementation, the 1.3-kb BamHI fragment of Tn903, which encodes amino-glycoside transferase (aph), was inserted into several different sites in pY6006 insert DNA, the resultant plasmids were reintroduced into the E. coli pyrF mutant strain, and the ability of the new plasmids to complement the mutant phenotype was assessed as before (FIG. 1). One of the three plasmids with insertion mutations, pY6006B, lost the ability to complement the pyrF mutant phenotype, suggesting that sequences necessary for the complementing activity are located in the vicinity of the BamHI site that is disrupted in pY6006B.

Analysis of DNA sequences for the left end of pY6006 insert DNA (as diagrammed in FIG. 1) revealed that the open reading frame of the pUC19 lacZ gene in this plasmid continues uninterrupted into an open reading frame for a polypeptide similar in sequence to OMP decarboxylase proteins. This preliminary data suggested that the left end of pY6006 insert DNA encoded the amino-terminus of the BCG OMP decarboxylase protein.

For later experiments, it was important to have both the OMP decarboxylase gene and a substantial amount of flanking sequences. To obtain genomic DNA that contains both the OMP decarboxylase gene and its flanking sequences, the 0.6 kb BamHI DNA fragment from pY6006 was used to probe a λgt11 library, of M. bovis BCG DNA, as the λgt11 library contains insert DNA fragments whose size, on average, is larger (4-8 kb) than the plasmid library used to obtain pY6006. A lambda clone (Y3030) was isolated which contains a 5.6 kb EcoRI DNA insert that overlaps that of pY6006. The 5.6 kb EcoRI DNA fragment, and a 4.4 kb SacI-EcoRI subfragment, were subcloned into plasmid vectors to generate pY6011 and pY6014, respectively (FIG. 1). Both pY6011 and pY6014 were able to complement the defect of the E. coli pyrF mutant strain Y1107.

Sequence of the BCG OMP decarboxylase gene and flanking DNA. DNA fragments, from phage Y3030 insert DNA were subcloned into M13 vectors and subjected to sequence analysis. Sequences were determined for both DNA strands, and most of the sequence reactions were duplicated with ITP replacing GTP to minimize artifacts due to the GC-rich nature of mycobacterial DNA. FIGS. 2A-2D shows the sequences obtained for the BCG OMP decarboxylase gene (uraA) and for flanking DNA. The predicted BCG OMP decarboxylase protein sequence is 274 amino acids long, similar in size to other OMP decarboxylase proteins. When the BCG decarboxylase protein sequence was used to screen the available databases for similar sequences, the results revealed that the BCG protein is closely related to the Myxococcus xanthus OMP DCase (Kirnsey and Kaiser, J. Biol. Chem. 267:819-824, 1992) and more distantly related to the other known prokaryotic and eukaryotic OMP DCases. Comparison of the BCG and M. xanthus OMP decarboxylases reveals that 40% of the amino acid residues are identical. In contrast, only 17% of the residues of the BCG and E. coli proteins and 22% of the amino acids of the M. xanthus and E. coli proteins are identical, although there are a substantial number of conservative amino acid substitutions among these proteins. The relationship of M. xanthus OMP decarboxylase to homologues in other prokaryotes and in eukaryotes was recently described in some detail (Kimsey and Kaiser, J. Biol. Chem. 267:819-824, 1992). This comparative sequence analysis revealed that there are four regions which are more highly conserved, and the predicted BCG OMP decarboxylase also shares this feature with the other homologues. It is interesting to note that Mycobacteria and Myxococci both have GC-rich genomes, but this alone does not account for the degree of sequence conservation between the OMP decarboxylases from these two proaryotes; rather, the two genuses appear to be more closely related to one another than either is to the other prokaryotes for which OMP decarboxylase sequence are available.

Further analysis of the BCG genomic DNA sequences revealed that the 1.7 kb sequence upstream of OMP decarboxylase coding sequences contains a single large open reading frame. This open reading frame has no apparent beginning in the cloned DNA fragment, suggesting that it is the coding sequence for the carboxy-terminus of a larger protein. A screen of the sequence database revealed that the 497 amino acid residues of the predicted protein are highly homologous to the carboxyl termini of the large subunit of carbamoyl phosphate synthase. For example, the 497 amino acid carboxy terminus of the putative M. bovis BCG protein was 46% identical to the comparable segment of the E. coli carbarnoyl phosphate synthase subunit, which is encoded by the carB gene (Nyunoya and Lusty, Proc. Natl. Acad. Sci. USA 80:4629-4633, 1983). Thus, the BCG carB gene appears to be located just upstream of uraA. This is interesting because both carbamoyl phosphate synthase and OMP decarboxylase are involved in pyrimidine biosynthesis. Carbamoyl phosphate synthase catalyzes the first reaction in pyrimidine biosynthesis, the production of carbamoyl phosphate, while OMP decarboxylase catalyzes the last step in the biosynthesis of UMP.

Analysis of BCG DNA sequences downstream of the uraA gene revealed a single large open reading frame that continues through the right end of the sequenced DNA fragment. This open reading frame predicts a protein of 501 amino acids. A search of the computer database revealed that the protein predicted by this ORF is similar to previously described proteins from M. tuberculosis and M. leprae. The predicted BCG protein is similar to a putative M. tuberculosis antigen encoded downstream of the gene for the 65 kDa antigen (Shinnick, T. M., J. Bacteriol. 169:1080-1088, 1987) and to a M. leprae antigen that may be an integral membrane protein (Vega-Lopez et al., Infect. Immun. 61:2145-2154, 1993).

Southern analysis with whole genomic DNA revealed that there is a single copy of the uraA gene and flanking DNA in the BCG genome (see below). The relative positions of the BCG uraA gene and the portions of other genes identified through sequence analysis are summarized graphically in FIG. 1. The position of OMP decarboxylase sequences is consistent with the genetic analysis described above. The aph insertion mutations in plasmid pY6006 that adversely affected complementation of the E. coli OMP decarboxylase mutant occurred within OMP decarboxylase coding sequences. Conversely, the aph insertion mutations that did not affect complementation of the E. coli OMP decarboxylase mutant occurred outside of the BCG OMP decarboxylase coding sequences.

EXAMPLE 2

BCG transformation. BCG Pasteur (ATCC) was grown in log phase to an OD₆₀₀ of 0.5 in Middlebrook medium. BCG cells were harvested by centrifugation and washed twice with PBS (phosphate buffered saline) and resuspended in 1 mM MgCl (pH 7.2), 10% sucrose, 15% glycerol at a concentration of 10 OD₆₀₀ per ml. 0.4 ml of BCG cells was mixed with 2 ug of plasmid DNA and electroporated in a 0.2 cm cuvette. Electroporation settings were 2.5 kV potential and 25 μF capacitance. After electroporation, cells were resuspended in 10 ml Middlebrook medium and incubated at 37° for 2 hours before plating on Middlebrook agar containing 20 ug/ml kanamycin and, in some experiments, with uracil.

Southern blot analysis. Genomic DNAs from BCG strains were isolated as described above, digested with restiction enzymes, subjected to agarose gel electrophoresis in the presense of ethidium bromide, transferred to nitrocellulose, and probed with DNA labelled with 32P by random priming, all by standard procedure (Ausubel et al., Current protocol in molecular biology (1987). Green Publishing Associates and Wiley Interscience).

Introduction of foreign DNA into the BCG genome. Previous attempts to obtain homologous recombination in M. bovis BCG have apparently not been successful (Kalpana et al., Proc. Natl. Acad. Sci. USA 88:5433-5447, 1991; Young and Cole, J. Bacteriol. 175:1-6, 1993). It is possible that the efficiency of transformation has an influence on the ability to obtain homologous recombination. To maximize the transformation efficiency of BCG, we investigated the effect of adding glycine to the culture medium prior to harvesting cells for electroporation, as the presence of 1.5% glycine can affect the integrity of the cell wall and it seems to improve transformation efficiency in M. smegmatis (Mizuguchi and Takunaga, "Spheroplasts of Mycobacteria. 2. Infection of Phage and Its DNA on Glycine Treated Mycobacteria and Spheroplasts", Med. Biol., 77:57 1968). In addition, we compared the efficiency of electroporation of BCG cells in water relative to buffer. The autonomously replicating plasmid pYUB12 (Snapper et al., Mol. Microbiol. 4:1911-1919, 1988) was used to determine how these variables affected the relative efficiencies of transformation. The results are summarized in the Table under Experiment 1. Transformation efficiencies were improved substantially by exposing cultures to 1.5% glycine for 24 hours prior to harvest, and by performing the electroporation in water rather than in buffer.

                  TABLE     ______________________________________     BCG Transformation Efficiencies                        Electro-     Trans-   Glycine   poration Transformants/ug DNA     forming DNA.sup.a              Treatment.sup.b                        Medium.sup.c                                 Expt 1                                       Expt 2                                             Expt 3     ______________________________________     pYUB12   -         Buffer    50   --    --     pYUB12   +         Buffer   250   --    --     pYUB12   -         Water    500   --    --     pYUB12   +         Water    .sup. .sup. 10.sup.4                                             .sup. 10.sup.5     None     +         Water     8     6    35     p6015 (I)              -         Buffer   --     4    --     p6015 (I)              +         Buffer   --    22    --     p6015 (I)              -         Water    --    39    --     p6015 (I)              +         Water    --    98    500     ______________________________________      .sup.a The intact autonomously replicating plasmid pYUB12 was used as a      control and the linear insert DNA of plasmid pY6015  pY6015 (I)! was used      as integrating DNA.      .sup.b Glycine was added to 1.5% to BCG cultures 24 hours prior to      transformation.      .sup.c The buffer is 1 mM MgCl (pH 7.2), 10% sucrose, 15% glycerol.

Experiments with linearized DNA molecules in yeast indicate that the ends of linear DNA molecules are recombinogenic; these ends may facilitate homologous integration by invading genomic DNA at homologous sites to initiate recombination (Rothstein, R., Meth., Enzymol. 194:281-301 (1988)). The sequenced 4.4 kb BCG DNA fragment containing UraA was used to investigate whether cloned DNA sequences could integrate at the homologous locus in M. bovis BCG. To mark the DNA fragment, the OMP decarboxylase coding sequence was replaced with a kanomycin-resistance gene (aph) to create pY6015 (FIG. 3). This left intact approximately 1.5 kb of UraA flanking sequences that could be used to direct homologous integration. The transformation experiment described above for plasmid pYUB12 was repeated with pY6015 insert DNA, and the results are summarized in the Table under Experiment 2. Again, transformation efficiencies were improved substantially by exposing cultures to 1.5% glycine for 24 hours prior to harvest, and by performing the electroporation in water rather than in buffer. However, because the transformation efficiencies obtained with the linear DNA were low, we made one additional attempt to improve these efficiencies.

Cultures of M. bovis BCG and other slow growing mycobacteria contain large numbers of cells that are inviable or that have an exceedingly long lag time after plating. Some investigators have suggested that mycobacterial cells have an unusual ability to enter and maintain a dormant state, even when nutrients are available (Young and Cole, "Leprosy, Tuberculosis, and the New Genetics", J. Bacteriol., 175:1-6 1993). We reasoned that maintenance of BCG cultures in mid-log growth might maximize the fraction of cells that were undergoing DNA synthesis and were competent to take up DNA and to incorporate it into homologous sites in the genome. A third experiment was performed, in which BCG cultures were diluted approximately 1:4 every two days over a two-month period to ensure persistent log-phase growth before transformation. The results in the Table indicate that this approach produces a significant increase in the number of transformants obtained with either the autonomously replicating vector or the linear DNA fragment.

Ten of the BCG colonies obtained in the third experiment were selected for further study after growing to adequate size for picking (24 days after plating). The ten transformants were colony purified, and DNA was prepared from each. DNA preparations from the wild type strain and the ten transformants were digested with a variety of restriction endonucleases and Southern analysis revealed that the kanomycin-resistant BCG transformants all contained vector DNA integrated into the genome. In two of the ten transformants, the transforming DNA had integrated at the homologous locus. FIG. 5 shows representative results from Southern analysis of the wild type strain and one of the BCG recombinants in which the cloned DNA integrated at the homologous locus.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using not more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

    __________________________________________________________________________     SEQUENCE LISTING     (1) GENERAL INFORMATION:     (iii) NUMBER OF SEQUENCES: 2     (2) INFORMATION FOR SEQ ID NO:1:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 4394 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: double     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:     GAGCTCGACCCCGCCGCCGAAACAGAGGTGGCCCCGCAGACCGAAAGGCCCAAGGTGCTG60     ATCCTCGGTTCGGGGCCCAATCGGATCGGCCAGGGTATCGAGTTCGACTACAGCTGCGTA120     CACGCGGCAACCACGTTGAGCCAGGCTGGCTTTGAGACCGTGATGGTCAACTGCAACCCG180     GAGACCATGGTGTCCACCGACTTCGACACCGCGGACAGGTTGTACTTCGAGCCGTTGACG240     TTCGAGGACGTCTTGGAGGTCTACCACGCCGAAATGGAATCCGGTAGCGGTGGCCCGGGA300     GTGGCCGGCGTCATCGTGCAGCTCGGCGGCCAGACCCCGCTCGGCTGGCGCACCGGCTCG360     CCGACGCCGGGTCCCGCTCGTGGGCACCCACCGGAGGCCATCGACCTGGCCGAGGATGCG420     GCCGTTCGGCGACCTGCTGAGCGAGGACTGCCGGCGCCAAAGTACGGCACCGCAACCACT480     TTCGCCCAGGCCCGCCGGATCGCCGAGGAGATCGGCTATCCGGTGCTGGTGCGGCCGTCG540     TATGTGCTCGGTGGTCGCGGCATGGAGATCGTGTATGACGAAGAAACGTTGCAGGGCTAC600     ATCACCCGCGCCACTCAGCTATCCCCCGAACACCCGGTGCTCGTGCACCGCTTCCTCGAG660     GACGCGGTCGAGATCGACGTCGACGCTCTGTGTGATGGCGCCGAGGTCTATATCGGCGGA720     ATCATGGAGCACATCGAGGAGGCCGGCATCCACTCCGGTGACTCGGCCTGTGCGCTGCCA780     CCGGTCACGTTGGGCCGCAGCGACATCGAGAAGGTGCGTAAGGCCACTGAAGCCATTGCG840     CATGGCATCGGCGTGGTGGGGCTGCTCAACGTGCAGTCCGCGCTCAAGGATGACGTGCTC900     TACGTCCTGGAAGCCAACCCGAGAGCGAGCCGTACCGTTCCGTTTGTATCCAAGGCCACA960     GCGGTGCCACTCGCCAAGGCATGCGCCCGGATCATGTTGGGCGCCACCATTGCCCAGCTG1020     CGCGCCGAAGGCTTGCTGGCGGTCACCGGGGATGGCGCCCACGCGGCGCGAAACGCCCCC1080     ATCGCGGTCAACCAGGCCGTGTTGCCGTTTCACCGGTTCCGGCGCGCCGACGGGGCCGCC1140     ATCGACTCGCTACTCGGCCCGGAGATGAAATCGACCGGCGAGGTGATGGGCATCGACCGC1200     GACTTCGGCAGCCGGTTCGCCAAGAGCCAGACCGCCGCCTACGGGTCGCTGCCGGCCCAG1260     GGCACAGTGTTCGTGTCGGTGGCCAACCGGGACAAGCGGTCGCTGGTGTTTCCGGTCAAA1320     CCGATTGGCCCACCTGGGTTTTCGCGTCCTTGCCACCGAAGCACCGCAGAGATCTTGCGC1380     CGCAACGGTATTCCCTGCGACGACGTCCGCAAACATTTCGAGCCGGCGCAGCCCGGCCGC1440     CCCACAATGTCGGCGGTGGACGCGATCCGAGCCGGCGAGGTCAACATGGTGATCAACACT1500     CCCTATGGCAACTCCGGTCCGCGCATCGACGGCTATGAGATCCGTTCGGCGGCGGTGGCC1560     GGCAACATCCCGTGCATCACCACGGTGCAGGGCGCATCCGCCGCCGTGCAGGGGATAGAG1620     GCCGGGATCCGCGGCGACATCGGGGTGCGCTCCCTGCAGGAGCTGCACCGGGTGATCGGG1680     GGCGTCGAGCGGTGACCGGGTTCGGTCTCCGGTTGGCCGAGGCAAAGGCACGCCGCGGCC1740     CGTTGTGTCTGGGCATCGATCCGCATCCCGAGCTGCTGCGGGGCTGGGATCTGGCGACCA1800     CGGCCGACGGGCTGGCCGCGTTCTGCGACATCTGCGTACGGGCCTTCGCTGATTTCGCGG1860     TGGTCAAACCGCAGGTGGCGTTTTTTGAGTCATACGGGGCTGCCGGATTCGCGGTGCTGG1920     AGCGCACCATCGCGGAACTGCGGGCCGCAGACGTGCTGGTGTTGGCCGACGCCAAGCGCG1980     GCGACATTGGGGCGACCATGTCGGCGTATGCGACGGCCTGGGTGGGCGACTCGCCGCTGG2040     CCGCCGACGCCGTGACGGCCTCGCCCTATTTGGGCTTCGGTTCGCTGCGGCCGCTGCTAG2100     AGGTCGCGGCCGCCCACGGCCGAGGGGTGTTCGTGCTGGCGGCCACCTCCAATCCCGAGG2160     GTGCGGCGGTGCAGAATGCCGCCGCCGACGGCCGCAGCGTGGCCCAGTTGGTCGTGGACC2220     AGGTGGGGGCGGCCAACGAGGCGGCAGGACCCGGGCCCGGATCCATCGGCGTGGTCGTCG2280     GCGCAACGGCGCCACAGGCCCCCGATCTCAGCGCCTTCACCGGGCCGGTGCTGGTGCCCG2340     GCGTGGGGGTGCAGGGCGGGCGCCCGGAGGCGCTGGGCGGTCTGGGCGGGGCCGCATCGA2400     GCCAGCTGTTGCCCGCGGTGGCGCGCGAGGTCTTGCGGGCCGGCCCCGGCGTGCCCGAAT2460     TGCGCGCCGCGGGCGAACGGATGCGCGATGCCGTCGCCTATCTCGCTGCCGTGTAGCGGG2520     TGCCCTGCCACCGCGCCGCTAAATCCCACCAGCATGGGGTGGTGAGCCCAGCGCTCGTGT2580     GACCAAACTCACCGCCCTGGGCCGTCGTCACGCTGTGTTAACCTCTCGTTCAAATGATAT2640     TCATATTCAATAGTGGCGCTAAGTGTCCGGTTGAATCCCCGTTGAACCCCCAACAGATGG2700     AGTCTGTGTCGTGACGTTGCGAGTCGTTCCCGAAAGCCTGGCAGGCGCCAGCGCTGCCAT2760     CGAAGCAGTGACCGCTCGCCTGGCCGCCGCGCACGCCGCGGCGGCCCCGTTTATCGCGGC2820     GGTCATCCCGCCTGGGTCCGACTCGGTTTCGGTGTGCAACGCCGTTGAGTTCAGCGTTCA2880     CGGTAGTCAGCATGTGGCAATGGCCGCTCAGGGGGTTGAGGAGCTCGGCCGCTCGGGGGT2940     CGGGGTGGCCGAATCGGGTGCCAGTTATGCCGCTAGGATGCGCTGGCGGCGGCGTCGTAT3000     CTCAGCGGTGGGCTATGACCGAGCCGTGGATAGCCTTCCCTCCCGAGGTGCACTCGGCGA3060     TGCTGAACTACGGTGCGGGCGTTGGGCCGATGTTGATCTCCGCCACGCAGAATGGGGAGC3120     TCAGCGCCCAATACGCAGAAGCGGCATCCGAGGTCGAGGAATTGTTGGGGGTGGTGGCCT3180     CCGAGGGATGGCAGGGGCAAGCCGCCGAGGCGTTAGTCGCCGCGTACATGCCGTTTCTGG3240     CGTGGCTGATCCAAGCCAGCGCCGACTGCGTGGAAATGGCCGCCCAGCAACACGCCGTCA3300     TCGAGGCCTACACTGCCGCGGTAGAGCTGATGCCTACTCAGGTCGAACTGGCCGCCAACC3360     AAATCAAGCTCGCGGTGTTGGTAGCGACCAATTTCTTTGGCATCAACACCATTCCCATTG3420     CGATCAATGAGGCCGAGTACGTGGAGATGTGGGTTCGGGCCGCCACCACGATGGCGACCT3480     ATTCAACAGTCTCCAGATCGGCGCTCTCCGCGATGCCGCACACCAGCCCCCCGCCGCTGA3540     TCCTGAAATCCGATGAACTGCTCCCCGACACCGGGGAGGACTCCGATGAAGACGGCCACA3600     ACCATGGCGGTCACAGTCATGGCGGTCACGCCAGGATGATCGATAACTTCTTTGCCGAAA3660     TCCTGCGTGGCGTCAGCGCGGGCCGCATTGTTTGGGACCCCGTCAACGGCACCCTCAACG3720     GACTCGACTACGACGATTACGTCTACCCCGGTCACGCGATCTGGTGGCTGGCTCGAGGCC3780     TCGAGTTTTTTCAGGATGGTGAACAATTTGGCGAACTGTTGTTCACCAATCCGACTGGGG3840     CTTTTCAGTTCCTCCTCTACGTCGTTGTGGTGGATTTGCCGACGCACATAGCCCAGATCG3900     CTACCTGGCTGGGCCAGTACCCGCAGTTGCTGTCGGCTGCCCTCACTGGCGTCATCGCCC3960     ACCTGGGAGCAATAACTGGTTTGGCGGGCCTATCCGGCCTGAGCGCCATTCCGTCTGCTG4020     CGATACCCGCCGTTGTACCGGAGCTGACACCCGTCGCGGCCGCGCCGCCTATGTTGGCGG4080     TCGCCGGGGTGGGCCCTGCAGTCGCCGCGCCGGGCATGCTCCCCGCCTCAGCACCCGCAC4140     CGGCGGCAGCGGCCGGCGCCACCGCAGCCGGCCCGACGCCGCCGGCGACTGGTTTCGGAG4200     GGCTTCCCGCCCTACCTGGTCGGCGGTGGCGGCCCAGGAATAGGGTTCGGCTCGGGACAG4260     TCGGCCCACGCCAAGGCCGCGGCGTCCGATTCCGCTGCAGCCGAGTCGGCGGCCCAGGCC4320     TCGGCGCGTGCGCAGGCGCGTGCTGCACGGCGGGGCCGCTCGGCGGCAAGGCACGTGGCC4380     ATCGTGACGAATTC4394     (2) INFORMATION FOR SEQ ID NO:2:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1271 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:     GluLeuAspProAlaAlaGluThrGluValAlaProGlnThrGluArg     151015     ProLysValLeuIleLeuGlySerGlyProAsnArgIleGlyGlnGly     202530     IleGluPheAspTyrSerCysValHisAlaAlaThrThrLeuSerGln     354045     AlaGlyPheGluThrValMetValAsnCysAsnProGluThrMetVal     505560     SerThrAspPheAspThrAlaAspArgLeuTyrPheGluProLeuThr     65707580     PheGluAspValLeuGluValTyrHisAlaGluMetGluSerGlySer     859095     GlyGlyProGlyValAlaGlyValIleValGlnLeuGlyGlyGlnThr     100105110     ProLeuGlyTrpArgThrGlySerProThrProGlyProAlaArgGly     115120125     HisProProGluAlaIleAspLeuAlaGluAspAlaAlaValArgArg     130135140     ProAlaGluArgGlyLeuProAlaProLysTyrGlyThrAlaThrThr     145150155160     PheAlaGlnAlaArgArgIleAlaGluGluIleGlyTyrProValLeu     165170175     ValArgProSerTyrValLeuGlyGlyArgGlyMetGluIleValTyr     180185190     AspGluGluThrLeuGlnGlyTyrIleThrArgAlaThrGlnLeuSer     195200205     ProGluHisProValLeuValHisArgPheLeuGluAspAlaValGlu     210215220     IleAspValAspAlaLeuCysAspGlyAlaGluValTyrIleGlyGly     225230235240     IleMetGluHisIleGluGluAlaGlyIleHisSerGlyAspSerAla     245250255     CysAlaLeuProProValThrLeuGlyArgSerAspIleGluLysVal     260265270     ArgLysAlaThrGluAlaIleAlaHisGlyIleGlyValValGlyLeu     275280285     LeuAsnValGlnSerAlaLeuLysAspAspValLeuTyrValLeuGlu     290295300     AlaAsnProArgAlaSerArgThrValProPheValSerLysAlaThr     305310315320     AlaValProLeuAlaLysAlaCysAlaArgIleMetLeuGlyAlaThr     325330335     IleAlaGlnLeuArgAlaGluGlyLeuLeuAlaValThrGlyAspGly     340345350     AlaHisAlaAlaArgAsnAlaProIleAlaValAsnGlnAlaValLeu     355360365     ProPheHisArgPheArgArgAlaAspGlyAlaAlaIleAspSerLeu     370375380     LeuGlyProGluMetLysSerThrGlyGluValMetGlyIleAspArg     385390395400     AspPheGlySerArgPheAlaLysSerGlnThrAlaAlaTyrGlySer     405410415     LeuProAlaGlnGlyThrValPheValSerValAlaAsnArgAspLys     420425430     ArgSerLeuValPheProValLysArgLeuAlaHisLeuGlyPheArg     435440445     ValLeuAlaThrGluAlaProGlnArgSerCysAlaAlaThrValPhe     450455460     ProAlaThrThrSerAlaAsnIleSerSerArgArgSerProAlaAla     465470475480     ProGlnCysArgArgTrpThrArgSerGluProAlaArgSerThrTrp     485490495     MetThrGlyPheGlyLeuArgLeuAlaGluAlaLysAlaArgArgGly     500505510     ProLeuCysLeuGlyIleAspProHisProGluLeuLeuArgGlyTrp     515520525     AspLeuAlaThrThrAlaAspGlyLeuAlaAlaPheCysAspIleCys     530535540     ValArgAlaPheAlaAspPheAlaValValLysProGlnValAlaPhe     545550555560     PheGluSerTyrGlyAlaAlaGlyPheAlaValLeuGluArgThrIle     565570575     AlaGluLeuArgAlaAlaAspValLeuValLeuAlaAspAlaLysArg     580585590     GlyAspIleGlyAlaThrMetSerAlaTyrAlaThrAlaTrpValGly     595600605     AspSerProLeuAlaAlaAspAlaValThrAlaSerProTyrLeuGly     610615620     PheGlySerLeuArgProLeuLeuGluValAlaAlaAlaHisGlyArg     625630635640     GlyValPheValLeuAlaAlaThrSerAsnProGluGlyAlaAlaVal     645650655     GlnAsnAlaAlaAlaAspGlyArgSerValAlaGlnLeuValValAsp     660665670     GlnValGlyAlaAlaAsnGluAlaAlaGlyProGlyProGlySerIle     675680685     GlyValValValGlyAlaThrAlaProGlnAlaProAspLeuSerAla     690695700     PheThrGlyProValLeuValProGlyValGlyValGlnGlyGlyArg     705710715720     ProGluAlaLeuGlyGlyLeuGlyGlyAlaAlaSerSerGlnLeuLeu     725730735     ProAlaValAlaArgGluValLeuArgAlaGlyProGlyValProGlu     740745750     LeuArgAlaAlaGlyGluArgMetArgAspAlaValAlaTyrLeuAla     755760765     AlaValMetTrpGlnTrpProLeuArgGlyLeuArgSerSerAlaAla     770775780     ArgGlySerGlyTrpProAsnArgValProValMetProLeuGlyCys     785790795800     AlaGlyGlyGlyValValSerGlnArgTrpAlaMetThrGluProTrp     805810815     IleAlaPheProProGluValHisSerAlaMetLeuAsnTyrGlyAla     820825830     GlyValGlyProMetLeuIleSerAlaThrGlnAsnGlyGluLeuSer     835840845     AlaGlnTyrAlaGluAlaAlaSerGluValGluGluLeuLeuGlyVal     850855860     ValAlaSerGluGlyTrpGlnGlyGlnAlaAlaGluAlaLeuValAla     865870875880     AlaTyrMetProPheLeuAlaTrpLeuIleGlnAlaSerAlaAspCys     885890895     ValGluMetAlaAlaGlnGlnHisAlaValIleGluAlaTyrThrAla     900905910     AlaValGluLeuMetProThrGlnValGluLeuAlaAlaAsnGlnIle     915920925     LysLeuAlaValLeuValAlaThrAsnPhePheGlyIleAsnThrIle     930935940     ProIleAlaIleAsnGluAlaGluTyrValGluMetTrpValArgAla     945950955960     AlaThrThrMetAlaThrTyrSerThrValSerArgSerAlaLeuSer     965970975     AlaMetProHisThrSerProProProLeuIleLeuLysSerAspGlu     980985990     LeuLeuProAspThrGlyGluAspSerAspGluAspGlyHisAsnHis     99510001005     GlyGlyHisSerHisGlyGlyHisAlaArgMetIleAspAsnPhePhe     101010151020     AlaGluIleLeuArgGlyValSerAlaGlyArgIleValTrpAspPro     1025103010351040     ValAsnGlyThrLeuAsnGlyLeuAspTyrAspAspTyrValTyrPro     104510501055     GlyHisAlaIleTrpTrpLeuAlaArgGlyLeuGluPhePheGlnAsp     106010651070     GlyGluGlnPheGlyGluLeuLeuPheThrAsnProThrGlyAlaPhe     107510801085     GlnPheLeuLeuTyrValValValValAspLeuProThrHisIleAla     109010951100     GlnIleAlaThrTrpLeuGlyGlnTyrProGlnLeuLeuSerAlaAla     1105111011151120     LeuThrGlyValIleAlaHisLeuGlyAlaIleThrGlyLeuAlaGly     112511301135     LeuSerGlyLeuSerAlaIleProSerAlaAlaIleProAlaValVal     114011451150     ProGluLeuThrProValAlaAlaAlaProProMetLeuAlaValAla     115511601165     GlyValGlyProAlaValAlaAlaProGlyMetLeuProAlaSerAla     117011751180     ProAlaProAlaAlaAlaAlaGlyAlaThrAlaAlaGlyProThrPro     1185119011951200     ProAlaThrGlyPheGlyGlyLeuProAlaLeuProGlyArgArgTrp     120512101215     ArgProArgAsnArgValArgLeuGlyThrValGlyProArgGlnGly     122012251230     ArgGlyValArgPheArgCysSerArgValGlyGlyProGlyLeuGly     123512401245     AlaCysAlaGlyAlaCysCysThrAlaGlyProLeuGlyGlyLysAla     125012551260     ArgGlyHisArgAspGluPhe     12651270     __________________________________________________________________________ 

We claim:
 1. A DNA construct consisting essentially of:a) DNA homologous to genomic DNA of a slow-growing mycobacterium; and b) DNA nonhomologous to genomic DNA of the slow-growing mycobacterium,wherein, upon introduction into a slow-growing mycobacterium, the DNA construct integrates by homologous recombination into genomic DNA of the slow-growing mycobacterium and, after integration into the genomic DNA, the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is expressed by the slow-growing mycobacterium or alters expression of a gene in the slow-growing mycobacterium.
 2. A homologously recombinant slow-growing mycobacterium comprising heterologous DNA, wherein the heterologous DNA has replaced genomic DNA of the slow-growing mycobacterium by homologous recombination with the genomic DNA.
 3. The homologously recombinant slow-growing mycobacterium of claim 2, wherein the heterologous DNA is a genetic marker.
 4. The homologously recombinant slow-growing mycobacterium of claim 3, wherein the slow-growing mycobacterium is Mycobacterium bovis BCG and the genetic marker is the orotidine-5-monophosphate decarboxylase gene locus.
 5. The homologously recombinant slow-growing mycobacterium of claim 2, wherein the heterologous DNA additionally comprises DNA nonhomologous to genomic DNA of the slow-growing mycobacterium.
 6. The homologously recombinant slow-growing mycobacterium of claim 5, wherein the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is DNA encoding a protein or polypeptide selected from the group consisting of: antigens, enzymes, lymphokines and immunopotentiators.
 7. The homologously recombinant slow-growing mycobacterium of claim 5, wherein the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is DNA encoding an antigen of a pathogen.
 8. The homologously recombinant slow-growing mycobacterium of claim 2, wherein the heterologous DNA which has replaced genomic DNA of the slow-growing mycobacterium is not expressed by the homologously recombinant slow-growing mycobacterium and inactivates or activates a gene in the slow-growing mycobacterium.
 9. A homologously recombinant slow-growing mycobacterium having incorporated into its genomic DNA heterologous DNA, wherein the homologously recombinant slow-growing mycobacterium is produced by a method comprising the steps of:a) combining a slow-growing mycobacterium and heterologous DNA to be transformed into the slow-growing mycobacterium, the heterologous DNA comprising DNA homologous to genomic DNA of the slow-growing mycobacterium, thereby producing a combination; and b) subjecting the combination produced in (a) to electroporation, under conditions sufficient for introduction of the heterologous DNA into the slow-growing mycobacterium and incorporation into the genomic DNA by homologous recombination at a homologous locus.
 10. The homologously recombinant slow-growing mycobacterium of claim 9 wherein the slow-growing mycobacterium of step (a) has been exposed to glycine prior to being combined with the heterologous DNA.
 11. The homologously recombinant slow-growing mycobacterium of claim 10 wherein the slow-growing mycobacterium is selected from the group consisting of: Mycobacterium bovis BCG, Mycobacterium tuberculosis, Mycobacterium leprae, Mycobacterium avium, Mycobacterium africanum and Mycobacterium intracellulare.
 12. The homologously recombinant slow-growing mycobacterium of claim 10 wherein the heterologous DNA additionally comprises DNA nonhomologous to genomic DNA of the slow-growing mycobacterium combined in step (a) with the heterologous DNA.
 13. The homologously recombinant slow-growing mycobacterium of claim 12 wherein the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is DNA encoding a protein or polypeptide selected from the group consisting of: antigens, enzymes, lymphokines, and immunopotentiators.
 14. The homologously recombinant slow-growing mycobacterium of claim 12, wherein the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is DNA encoding an antigen of a pathogen.
 15. The homologously recombinant slow-growing mycobacterium of claim 12 wherein the slow-growing mycobacterium is Mycobacterium bovis BCG and the DNA homologous to genomic DNA of the slow-growing mycobacterium is DNA contained in the Mycobacterium bovis BCG orotidine-5-monophosphate decarboxylase gene locus or flanking sequences thereof.
 16. The homologously recombinant slow-growing mycobacterium of claim 10, wherein the heterologous DNA which is incorporated into the genomic DNA of the slow-growing mycobacterium is not expressed by the homologously recombinant slow-growing mycobacterium and inactivates or activates a gene in the slow-growing mycobacterium.
 17. A homologously recombinant slow-growing mycobacterium having heterologous DNA integrated into its genomic DNA, wherein the homologously recombinant slow-growing mycobacterium is produced by a method comprising the steps of:a) combining a slow-growing mycobacterium and heterologous DNA to be transformed into the slow-growing mycobacterium, thereby producing a combination; and b) subjecting the combination produced in (a) to electroporation; under conditions sufficient for introduction of the heterologous DNA into the slow-growing mycobacterium and integration into the genomic DNA.
 18. The homologously recombinant slow-growing mycobacterium of claim 17 wherein the slow-growing mycobacterium of step (a) has been exposed to glycine prior to being combined with the heterologous DNA.
 19. The homologously recombinant slow-growing mycobacterium of claim 18 wherein the slow-growing mycobacterium is selected from the group consisting of: Mycobacterium bovis BCG, Mycobacterium tuberculosis, Mycobacterium leprae, Mycobacterium avium, Mycobacterium africanum and Mycobacterium intracellulare.
 20. The homologously recombinant slow-growing mycobacterium of claim 19 wherein the heterologous DNA additionally comprises DNA nonhomologous to genomic DNA of the slow-growing mycobacterium combined in step (a) with the heterologous DNA.
 21. The homologously recombinant slow-growing mycobacterium of claim 20 wherein the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is DNA encoding a protein or polypeptide selected from the group consisting of: antigens, enzymes, lymphokines and immunopotentiators.
 22. The homologously recombinant slow-growing mycobacterium of claim 20, wherein the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is DNA encoding an antigen of a pathogen.
 23. The homologously recombinant slow-growing mycobacterium of claim 20 wherein the slow-growing mycobacterium is Mycobacterium bovis BCG and the DNA homologous to genomic DNA of the slow-growing mycobacterium is DNA contained in the Mycobacterium bovis BCG orotidine-5-monophosphate decarboxylase gene locus or flanking sequences thereof.
 24. The homologously recombinant slow-growing mycobacterium of claim 19, wherein the heterologous DNA which is integrated into the genomic DNA of the slow-growing mycobacterium is not expressed by the homologously recombinant slow-growing mycobacterium and inactivates or activates a gene in the slow-growing mycobacterium.
 25. The DNA construct of claim 1, wherein the slow-growing mycobacterium is Mycobacterium bovis BCG and the DNA homologous to genomic DNA of the slow-growing mycobacterium is DNA contained in the orotidine-5-monophosphate decarboxylase gene locus.
 26. The homologously recombinant slow-growing mycobacterium of claim 2, wherein the heterologous DNA comprises at least about 250 bp of DNA homologous to genomic DNA of the slow-growing mycobacterium.
 27. The homologously recombinant slow-growing mycobacterium of claim 2, wherein the slow-growing mycobacterium is selected from the group consisting of: Mycobacterium bovis BCG, Mycobacterium tuberculosis, Mycobacterium leprae, Mycobacterium avium, Mycobacterium africanum and Mycobacterium intracellulare.
 28. The homologously recombinant slow-growing mycobacterium of claim 9, wherein in step a), the DNA homologous to genomic DNA of the slow-growing mycobacterium comprises at least about 250 bp.
 29. A homologouoly recombinant slow-growing mycobacterium produced by homologous recombination between genomic DNA of a slow-growing mycobacterium and heterologous DNA, wherein the heterologous DNA has replaced the genomic DNA and comprises at least about 250 bp of DNA homologous to the genomic DNA of the slow-growing mycobacterium.
 30. The homologously recombinant slow-growing mycobacterium of claim 29, wherein the slow-growing mycobacterium is selected from the group consisting of: Mycobacterium bovis BCG, Mycobacterium tuberculosis, Mycobacterium leprae, Mycobacterium avium, Mycobacterium africanum and Mycobacterium intracellulare.
 31. The homologously recombinant slow-growing mycobacterium of claim 29, wherein the heterologous DNA which has replaced the genomic DNA of the slow-growing mycobacterium is not expressed by the homologously recombinant slow-growing mycobacterium and inactivates or activates a gene in the slow-growing mycobacterium.
 32. The homologously recombinant slow-growing mycobacterium of claim 29, wherein the heterologous DNA additionally comprises DNA nonhomologous to genomic DNA of the slow-growing mycobacterium.
 33. The homologously recombinant slow-growing mycobacterium of claim 32, wherein the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is DNA encoding a protein or polypeptide selected from the group consisting of: antigens, enzymes, lymphokines, and immunopotentiators.
 34. The homologously recombinant slow-growing mycobacterium of claim 32, wherein the DNA nonhomologous to genomic DNA of the slow-growing mycobacterium is DNA encoding an antigen of a pathogen.
 35. The homologously recombinant slow-growing mycobacterium of claim 29, wherein the slow-growing mycobacterium is Mycobacterium bovis BCG and the heterologous DNA is DNA contained in the orotidine-5-monophosphate decarboxylase gene locus.
 36. A homologously recombinant slow-growing mycobacterium produced by introducing the DNA construct of claim 1 into a slow-growing mycobacterium. 